Scandion Oncology A/S (SCOL.ST)
SEK 0.01
(-5.04%)
SEK 0.01
(-5.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -39.2 Million DKK | 48.89% |
| 2022 | -76.7 Million DKK | -48.34% |
| 2021 | -51.7 Million DKK | -217.81% |
| 2020 | -16.26 Million DKK | -33.53% |
| 2019 | -12.18 Million DKK | -48.9% |
| 2018 | -8.18 Million DKK | -438.59% |
| 2017 | -1.51 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.56 Million DKK | 31.12% |
| 2024 Q2 | -7.16 Million DKK | 5.35% |
| 2023 Q4 | -10.98 Million DKK | -8.23% |
| 2023 Q2 | -8.77 Million DKK | 5.53% |
| 2023 FY | -39.2 Million DKK | 48.89% |
| 2023 Q1 | -9.28 Million DKK | 33.4% |
| 2023 Q3 | -10.15 Million DKK | -15.72% |
| 2022 Q2 | -23.02 Million DKK | -78.19% |
| 2022 Q4 | -13.94 Million DKK | 48.09% |
| 2022 FY | -76.7 Million DKK | -48.34% |
| 2022 Q1 | -12.91 Million DKK | 14.4% |
| 2022 Q3 | -26.86 Million DKK | -16.69% |
| 2021 Q1 | -8.76 Million DKK | -68.54% |
| 2021 FY | -51.7 Million DKK | -217.81% |
| 2021 Q4 | -15.09 Million DKK | 1.41% |
| 2021 Q3 | -15.3 Million DKK | -22.05% |
| 2021 Q2 | -12.54 Million DKK | -43.17% |
| 2020 Q2 | -3.4 Million DKK | 9.8% |
| 2020 Q1 | -3.77 Million DKK | -3426.83% |
| 2020 Q4 | -5.19 Million DKK | -33.57% |
| 2020 FY | -16.26 Million DKK | -33.53% |
| 2020 Q3 | -3.89 Million DKK | -14.3% |
| 2019 Q4 | -107.02 Thousand DKK | 98.29% |
| 2019 FY | -12.18 Million DKK | -48.9% |
| 2019 Q3 | -6.25 Million DKK | -61.26% |
| 2019 Q2 | -3.87 Million DKK | -98.97% |
| 2019 Q1 | -1.94 Million DKK | 59.24% |
| 2018 Q2 | -1.69 Million DKK | -212.28% |
| 2018 Q4 | -4.78 Million DKK | -371.67% |
| 2018 FY | -8.18 Million DKK | -438.59% |
| 2018 Q1 | -542.2 Thousand DKK | 8.21% |
| 2018 Q3 | -1.01 Million DKK | 40.14% |
| 2017 Q3 | -422.16 Thousand DKK | 0.0% |
| 2017 FY | -1.51 Million DKK | 0.0% |
| 2017 Q4 | -590.67 Thousand DKK | -39.92% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcouSort AB (publ) | -17.08 Million SEK | -129.411% |
| Active Biotech AB (publ) | -45.8 Million SEK | 14.402% |
| Alzinova AB (publ) | -16.48 Million SEK | -137.888% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -205.613% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 84.229% |
| BioArctic AB (publ) | 229.24 Million SEK | 117.101% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 91.59% |
| Camurus AB (publ) | 431.44 Million SEK | 109.087% |
| Cantargia AB (publ) | -280.02 Million SEK | 86.0% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -85.88% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 74.182% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 65.405% |
| Kancera AB (publ) | -64.88 Million SEK | 39.583% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 827.887% |
| LIDDS AB (publ) | -40.2 Million SEK | 2.492% |
| Lipum AB (publ) | -37.17 Million SEK | -5.449% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -223.252% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 422.163% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -119.053% |
| NextCell Pharma AB | -41.95 Million SEK | 6.568% |
| Saniona AB (publ) | -95.81 Million SEK | 59.082% |
| Simris Alg AB (publ) | -37.3 Million SEK | -5.09% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 87.392% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -139.078% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 89.9% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 78.18% |
| Amniotics AB (publ) | -30.87 Million SEK | -26.997% |
| CombiGene AB (publ) | -35.66 Million SEK | -9.922% |
| Genovis AB (publ.) | 61.5 Million SEK | 163.746% |
| Mendus AB (publ) | -101.61 Million SEK | 61.421% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -5.754% |
| OncoZenge AB (publ) | -15.9 Million SEK | -146.535% |
| Xintela AB (publ) | -54.08 Million SEK | 27.511% |
| Ziccum AB (publ) | -21.41 Million SEK | -83.094% |
| Intervacc AB (publ) | -102.85 Million SEK | 61.883% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -8850.685% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -137.269% |
| Corline Biomedical AB | -1.8 Million SEK | -2067.164% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 77.955% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 31.004% |
| Aptahem AB (publ) | -11.11 Million SEK | -252.78% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 68.144% |
| Fluicell AB (publ) | -26.55 Million SEK | -47.639% |
| Biovica International AB (publ) | -124.82 Million SEK | 68.592% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 7.15% |
| Abliva AB (publ) | -95.5 Million SEK | 58.953% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 88.007% |
| 2cureX AB (publ) | -32.51 Million SEK | -20.561% |
| I-Tech AB | 20.2 Million SEK | 294.05% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.286% |
| Cyxone AB (publ) | -22.98 Million SEK | -70.534% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 57.108% |
| Biosergen AB | -27.03 Million SEK | -45.001% |
| Nanologica AB (publ) | -75.15 Million SEK | 47.837% |
| SynAct Pharma AB | -215.81 Million SEK | 81.834% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 11.009% |
| BioInvent International AB (publ) | -330.3 Million SEK | 88.131% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -65.16% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 84.262% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -294.803% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 64.128% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -235.708% |